Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-4774 in virally suppressed chronic hepatitis B subjects on oral antivirals
ACTRN12613001080718Phase 2Recruiting
- Sponsor
- Gilead Sciences
- Start
- Sep 2013
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of GS-4774 in Chronic Hepatitis B (CHB) (4 arms), sponsored by Gilead Sciences. Primary endpoints: Safety and tolerability of GS-4774 and Change from baseline in serum hepatitis B surface antigen. Started Sep 2013; status: recruiting.
02
Drugs
GS-4774
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ACTRN12613001080718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001080718.